Retrospective Cohort Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Aug 14, 2016; 22(30): 6925-6935
Published online Aug 14, 2016. doi: 10.3748/wjg.v22.i30.6925
Figure 1
Figure 1 Immunohistochemistry of the spleen for CD20+ B-cell follicles and CD 138+ plasma cells. Reduced size of B-cell follicles after rituximab prophylaxis in the spleen (A) compared to a control (B) (× 40). Plasma cells in the spleen with rituximab prophylaxis (C) and without (D) (× 400).
Figure 2
Figure 2 Liver biopsy pathology of case No. 12. Non-specific inflammation shown by H&E staining (A) (× 400). CD 56+ cells (black arrows) embedded in liver parenchyma (B) (× 400). The patient developed ITBL 23 d after the liver biopsy.
Figure 3
Figure 3 Overall survivals rates after adult living donor liver transplantation. 1-, 3-, and 5-yr survival rates are 93.9%, 84.8%, and 82% after ABO-identical/compatible ALDLT and 92.6%, 81.5%, and 73.0% after ABO-I ALDLT. There is no statistical difference between survival rates of the two groups (P = 0.303). ALDLT: Adult living donor liver transplantation.
Figure 4
Figure 4 Ischemic-type biliary lesion diagnosed by the cholangiogram via external biliary stent. Diffuse dilatations of the intrahepatic bile ducts with irregularities are shown.